BTIG lowered the firm’s price target on Sophia Genetics (SOPH) to $5 from $6 and keeps a Buy rating on the shares. The company turned in a relatively challenging 2024 as they drove 4% revenue growth while growing their volumes by 11%, which implies a 6%-7% decline in revenue per analysis, the analyst tells investors in a research note. BTIG adds however that Sophia expects a return to double-digit revenue growth in 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOPH:
- SOPHiA GENETICS: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- SOPHiA GENETICS Reports 2024 Financial Results
- SOPHiA GENETICS Earnings Call: Mixed Results, Optimistic Outlook
- SOPHiA GENETICS Reports 2024 Financial Results and Sets Growth Path for 2025
- Sophia Genetics reports Q4 EPS (23c), consensus (15c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue